Abstract
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that resides at the sites of at focal adhesions. The 125 kDa FAK protein is encoded by the FAK gene located on human chromosome 8q24. Structurally, FAK consists of an amino-terminal regulatory FERM domain, a central catalytic kinase domain, and a carboxy-terminal focal adhesion targeting domain. FAK has been shown to be an important mediator of cell adhesion, growth, proliferation, survival, angiogenesis and migration, all of which are often disrupted in cancer cells. Normal tissues have low expression of FAK, while primary and metastatic tumors significantly overexpress this protein. This review summarizes expression of FAK by immunohistochemical staining in different tumor types and presents several FAK inhibition therapy approaches.
Keywords: Adhesion, cancer, Focal Adhesion Kinase, inhibitor, metastasis, tumor, Breast Cancer, Hepatocellular Carcinoma, Acute Myeloid Leukemia, HBV, FRNK, Troglitazone, Neuroblastoma, IHC, EGFR
Anti-Cancer Agents in Medicinal Chemistry
Title: Focal Adhesion Kinase as a Cancer Therapy Target
Volume: 10 Issue: 10
Author(s): Vita M. Golubovskaya
Affiliation:
Keywords: Adhesion, cancer, Focal Adhesion Kinase, inhibitor, metastasis, tumor, Breast Cancer, Hepatocellular Carcinoma, Acute Myeloid Leukemia, HBV, FRNK, Troglitazone, Neuroblastoma, IHC, EGFR
Abstract: Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that resides at the sites of at focal adhesions. The 125 kDa FAK protein is encoded by the FAK gene located on human chromosome 8q24. Structurally, FAK consists of an amino-terminal regulatory FERM domain, a central catalytic kinase domain, and a carboxy-terminal focal adhesion targeting domain. FAK has been shown to be an important mediator of cell adhesion, growth, proliferation, survival, angiogenesis and migration, all of which are often disrupted in cancer cells. Normal tissues have low expression of FAK, while primary and metastatic tumors significantly overexpress this protein. This review summarizes expression of FAK by immunohistochemical staining in different tumor types and presents several FAK inhibition therapy approaches.
Export Options
About this article
Cite this article as:
M. Golubovskaya Vita, Focal Adhesion Kinase as a Cancer Therapy Target, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (10) . https://dx.doi.org/10.2174/187152010794728648
DOI https://dx.doi.org/10.2174/187152010794728648 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ionic Liquids for Topical Delivery in Cancer
Current Medicinal Chemistry Inhibiting Cyclin-Dependent Kinase / Cyclin Activity for the Treatment of Cancer and Cardiovascular Disease
Current Pharmaceutical Biotechnology Transmission and Immunopathogenesis of FIV in Cats as a Model for HIV
Current HIV Research Predictors and Clinical Implications of HPV Reservoire Districts for Genital Tract Disease
Current Pharmaceutical Design Nicotine Vaccines
CNS & Neurological Disorders - Drug Targets Women’s Ginseng (Angelica sinensis): An Ethnopharmacological Dossier
Current Traditional Medicine Overview of SLC22A and SLCO Families of Drug Uptake Transporters in the Context of Cancer Treatments
Current Drug Metabolism Chemistry of Bis-Spiroacetal Systems: Natural Products, Synthesis and Stereochemistry
Current Organic Chemistry Diarylurea: A Privileged Scaffold in Drug Discovery and Therapeutic Development
Current Medicinal Chemistry Glucose Transporters in Sex Steroid Hormone Related Cancer
Current Vascular Pharmacology Recent Development in Applications of Important Biopolymer Chitosan in Biomedicine, Pharmaceuticals and Personal Care Products
Current Tissue Engineering (Discontinued) Pediatric Differentiated Thyroid Cancer: When to Perform Conservative and Radical Surgery
Current Pediatric Reviews The Chemistry and Pharmacology of Genistein
The Natural Products Journal Derivatives of Procaspase-Activating Compound 1 (PAC-1) and their Anticancer Activities
Current Medicinal Chemistry Intranasal Drug Delivery for Brain Targeting
Current Drug Delivery Stilbenes and Xanthones from Medicinal Plants as Potential Antitumor Agents
Current Bioactive Compounds The Immunohistochemical Assessment of HPV Related Adenocarcinoma: Pathologic and Clinical Prognostic Significance
Current Pharmaceutical Design Targeted Therapy of the Insulin-Like Growth Factor-1 Receptor in Cancer
Combinatorial Chemistry & High Throughput Screening Advanced Vectors for Gene Delivery
Current Drug Therapy Wnt/β-catenin Antagonists: Exploring New Avenues to Trigger Old Drugs in Alleviating Glioblastoma Multiforme
Current Molecular Pharmacology